We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SGTX

Price
-
Stock movement up
+- (%)
Company name
Sigilon Therapeutics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
56.22M
Ent value
64.71M
Price/Sales
3.18
Price/Book
2.05
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
152.15%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2024-12-17

DIVIDENDS

SGTX does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF3.18
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.18
Price to Book2.05
EV to Sales3.67

FINANCIALS

Per share

Loading...
Per share data
Current share count2.50M
EPS (TTM)-11.82
FCF per share (TTM)7.08

Income statement

Loading...
Income statement data
Revenue (TTM)17.65M
Gross profit (TTM)17.65M
Operating income (TTM)-30.84M
Net income (TTM)-29.57M
EPS (TTM)-11.82
EPS (1y forward)-13.01

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-174.66%
Profit margin (TTM)-167.52%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash19.62M
Net receivables6.86M
Total current assets44.87M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets55.56M
Accounts payable1.11M
Short/Current long term debt7.39M
Total current liabilities25.25M
Total liabilities28.11M
Shareholder's equity27.45M
Net tangible assets27.45M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-32.76M
Capital expenditures (TTM)521.00K
Free cash flow (TTM)17.70M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-107.75%
Return on Assets-53.23%
Return on Invested Capital-92.51%
Cash Return on Invested Capital55.37%

STOCK INFORMATION

Downside potential

Loading...
Downside potential data
SGTXS&P500
Current price drop from All-time high-96.40%-8.63%
Highest price drop-99.39%-56.47%
Date of highest drop27 Dec 20229 Mar 2009
Avg drop from high-85.99%-11.07%
Avg time to new high170 days12 days
Max time to new high662 days1805 days
COMPANY DETAILS
SGTX (Sigilon Therapeutics Inc) company logo
Marketcap
56.22M
Marketcap category
Small-cap
Description
Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees
62
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner